Literature DB >> 2746493

Kinetic and dynamic study of intravenous lorazepam: comparison with intravenous diazepam.

D J Greenblatt1, B L Ehrenberg, J Gunderman, J M Scavone, N T Tai, J S Harmatz, R I Shader.   

Abstract

Six healthy volunteers received a single i.v. dose of 'low dose' lorazepam (0.0225 mg/kg), 'high dose' lorazepam (0.045 mg/kg) and placebo by 1-min infusion in a double-blind three-way crossover study. Plasma concentrations were measured 24 hr after dosage, and the EEG power spectrum was simultaneously computed by fast-Fourier transform to determine the percentage of total EEG amplitude occurring in the 13-30-Hz range. Low and high dose lorazepam did not differ significantly in distribution volume (1.89 versus 1.81 l/kg) or elimination half-life (11.5 versus 12.2 hr); clearance was slightly although significantly reduced at the higher dose (2.08 versus 1.88 ml/min/kg, P less than .005). EEG effects were of relatively slow onset, reaching their maximum change over baseline 30 min after infusion. The duration of action was prolonged, with the fraction of EEG activity in the 13-30-Hz range still significantly above baseline 8 hr after the 0.045 mg/kg dose. Five of these subjects received 0.15 mg/kg of i.v. diazepam in a companion study of identical design. EEG effects of diazepam were shorter than those of lorazepam, probably because of the more rapid and extensive decline in plasma diazepam concentrations in the postinfusion distribution phase. In addition, the onset of diazepam's effect was immediate. In male CD-1 mice that received i.v. diazepam (8.3 mg/kg) or lorazepam (3.3 mg/kg), the brain:plasma concentration ratio was maximal 2.5 min after dosage for diazepam, but equilibration was delayed at least 30 min after dosage for lorazepam. Thus the slow onset of action of lorazepam is probably attributable to slow entry into brain.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2746493

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  23 in total

Review 1.  Comparative tolerability of sedative agents in head-injured adults.

Authors:  Susan C Urwin; David K Menon
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

Review 2.  Pharmacokinetic optimisation of antiemetic therapy.

Authors:  M Campbell; D N Bateman
Journal:  Clin Pharmacokinet       Date:  1992-08       Impact factor: 6.447

Review 3.  Electroencephalogram effect measures and relationships between pharmacokinetics and pharmacodynamics of centrally acting drugs.

Authors:  J W Mandema; M Danhof
Journal:  Clin Pharmacokinet       Date:  1992-09       Impact factor: 6.447

4.  Pharmacokinetic considerations for moderate and deep sedation.

Authors:  Daniel E Becker
Journal:  Anesth Prog       Date:  2011

Review 5.  Pharmacodynamic considerations for moderate and deep sedation.

Authors:  Daniel E Becker
Journal:  Anesth Prog       Date:  2012

6.  Intranasal delivery--modification of drug metabolism and brain disposition.

Authors:  Yin Cheong Wong; Zhong Zuo
Journal:  Pharm Res       Date:  2010-04-06       Impact factor: 4.200

Review 7.  Treatment of patients with cocaine-induced arrhythmias: bringing the bench to the bedside.

Authors:  Robert S Hoffman
Journal:  Br J Clin Pharmacol       Date:  2010-05       Impact factor: 4.335

8.  The pharmacology of benzodiazepines: comments on terminology and sources of data.

Authors:  D J Greenblatt
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

9.  Comparative pharmacokinetics of alprazolam and lorazepam in humans and in African Green Monkeys.

Authors:  H Friedman; D E Redmond; D J Greenblatt
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

Review 10.  Pharmacokinetic-pharmacodynamic relationships for benzodiazepines.

Authors:  B E Laurijssens; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  1996-01       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.